Company news

Telix Pharmaceuticals Limited news in 2024

Telix Pharmaceuticals Limited's news releases, calls and decks from 2024, newest first.

View company

Presentation to Accompany FAP-Targeting Acquisition

November 18, 2024

Telix Adds FAP-Targeting Theranostic Candidates to Pipeline

November 18, 2024

CMS payment improvement decision for radiopharma diagnostics

November 3, 2024

FDA accepts NDA and grants priority review for Pixclara

October 23, 2024

Telix Files Form 20-F Registration Statement for Nasdaq ADS

October 17, 2024

Telix Q3 2024 Revenue and Business Update

October 17, 2024

Telix to Acquire RLS for US Manufacturing and Distribution

September 22, 2024

Telix Submits NDA for TLX101-CDx Brain Cancer Imaging Agent

August 27, 2024

Telix 1H 2024 Results Release

August 22, 2024

Telix 1H 2024 Results Presentation

August 22, 2024

Telix 1H 2024 Appendix 4D and Interim Report

August 22, 2024

Telix Completes A$650 Million of Convertible Bonds

July 30, 2024

Convertible Bond Cleansing Notice

July 29, 2024

Telix Successfully Prices A$650M Convertible Bonds

July 23, 2024

Telix Announces A$600 Million Convertible Bonds Offering

July 23, 2024

Telix Q2 2024 Revenue/Business Highlights, Guidance Upgrade

July 17, 2024

CMS proposes payment improvement for radiopharma diagnostics

July 11, 2024

Telix Elects to Withdraw from Proposed U.S. Listing

June 13, 2024

Trading Halt

June 12, 2024

Telix Launches Proposed US IPO

June 5, 2024

Telix Completes TLX250-CDx (Zircaix) BLA Submission

June 2, 2024

ProstACT SELECT Study of TLX591 rADC Therapy - Positive rPFS

May 30, 2024

Response to ASX Query

May 28, 2024

Telix Submits NDA for New Prostate Cancer Imaging Agent

May 26, 2024

Telix Annual General Meeting - Presentation

May 22, 2024

Telix Annual General Meeting - Chairman and CEO Addresses

May 22, 2024

Telix Completes Proof-of-Concept Study for Alpha Therapy

May 20, 2024

Telix has Filed Registration Statement for Proposed US IPO

May 19, 2024

Telix Reports Q1 2024 Financial Performance

May 17, 2024

Telix Completes Acquisition of QSAM

May 2, 2024

Telix Q1 2024 Revenue and Business Update

April 17, 2024

TLX101-CDx (Pixclara) Granted FDA Fast Track Designation

April 15, 2024

Telix Completes Acquisition of ARTMS

April 11, 2024

Telix Completes Acquisition of IsoTherapeutics

April 8, 2024

Telix General Meeting Presentation

April 4, 2024

Telix General Meeting Chairman and CEO Addresses

April 4, 2024

Telix to Acquire ARTMS (Isotope Production Platform)

March 4, 2024

Presentation to Accompany ARTMS Acquisition

March 4, 2024

Telix to Acquire IsoTherapeutics (US R&D and Manufacturing)

February 26, 2024

2023 Full Year Results Presentation

February 22, 2024

Appendix 4E and 2023 Annual Report

February 22, 2024

2023 Full Year Results Release

February 22, 2024

Telix Acquires QSAM and its Bone Cancer Targeting Platform

February 7, 2024

Presentation to Accompany QSAM Acquisition

February 7, 2024

JP Morgan Healthcare Conference Presentation

January 8, 2024

JP Morgan Healthcare Conference and Trading Update

January 8, 2024

Telix Plans U.S. Registered Public Offering and Listing

January 4, 2024

Decks in 2024